Dr. William Bennett
Add to your Care-Team
Dr. William Bennett
Dr. William Bennett
Internal Medicine - Nephrology & Dialysis
I specialize in
Internal Medicine - Nephrology & Dialysis
I have been in practice
I'm known for
My answers and insights have
Helped 100 people
Received 3 doctor agrees
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
Northwestern University Feinberg School of Medicine
Dr. William Bennett M
I've won the following awards
Top Doctors, Portland Monthly Magazine
AmericaÃ¢â¬â¢s Top Doctors, Castle Connolly
Jared J. Grantham Distinguished Achievement Award, Polycystic Kidney Research Foundation
Belding Scribner Award, American Society of Nephrology
First Gift of Life Award, Kidney Association of Oregon
Discovery Award, Medical Research Foundation of Oregon
Listed, America's Top Doctors
Listed, Best Doctors in America
Peritransplant management of retained native kidneys in autosomal dominant polycystic kidney disease.
Nephrol. Dial. Transplant., Jul (2012)
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol., Mar;7(3):479-86 (2012)
Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
Kidney Int., Dec;80(11):1122-37 (2011)
A new system for kidney allocation: the devil is in the details.
Clin J Am Soc Nephrol., Sep;6(9):2308-9 (2011)
George A. Porter, MD, 1931-2011: a distinguished academic career.
Am. J. Kidney Dis., May;57(5):xxi-xxii (2011)
mTOR inhibitors and autosomal dominant polycystic kidney disease.
N. Engl. J. Med., Jan;364(3):286-7; author reply 287-9 (2011)
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol., Mar;6(3):640-7 (2011)
Kidney transplantation in the morbidly obese: complicated but still better than dialysis.
Clin Transplant., 25(3):401-5 (2011 May-Jun)
Surveillance and modification of immunosuppression minimizes BK virus nephropathy.
Am. J. Nephrol., 32(1):10-2 (2010)
Extension of Medicare immunosuppressive drug benefits: a "no brainer" that did not happen.
Clin J Am Soc Nephrol., May;5(5):743 (2010)
Role of cellular cholesterol in pharmacologic preconditioning with cyclosporine in experimental kidney transplantation.
Am. J. Nephrol., 31(2):134-40 (2010)
Drug dosing in the elderly patients with chronic kidney disease.
Clin. Geriatr. Med., Aug;25(3):459-527 (2009)
Autosomal dominant polycystic kidney disease: 2009 update for internists.
Korean J. Intern. Med., Sep;24(3):165-8 (2009)
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.
Clin J Am Soc Nephrol., Apr;4(4):719-25 (2009)
Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation.
Transplantation., Feb;87(3):326-9 (2009)
Introduction: academic nephrology 2008.
Clin J Am Soc Nephrol., Nov;3(6):1869 (2008)
Clin J Am Soc Nephrol., Sep;3(5):1561-2 (2008)
Use of organs for transplantation from a donor with primary meningoencephalitis due to Naegleria fowleri.
Am. J. Transplant., Jun;8(6):1334-5 (2008)
Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen.
Clin J Am Soc Nephrol., Jul;2(4):694-9 (2007)
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol., Jan;2(1):112-20 (2007)
Patient care guidelines: problems and solutions.
Clin J Am Soc Nephrol., Jan;2(1):1-2 (2007)
Should dialysis patients ever receive warfarin and for what reasons?
Clin J Am Soc Nephrol., Nov;1(6):1357-9 (2006)
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
Clin J Am Soc Nephrol., Jan;1(1):64-9 (2006)
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.
J. Am. Soc. Nephrol., Jul;18(7):2143-60 (2007)
Increased vascular resistance and not salt retention characterizes cyclosporine A-induced hypertension: report in an anuric patient.
Am. J. Transplant., Aug;7(8):2042-6 (2007)
Renal transplantation for ADPKD patients: a 2007 update.
Nephrol News Issues., Mar;21(4):24-5, 27 (2007)
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.
J. Am. Soc. Nephrol., Nov;17(11):3013-9 (2006)
Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.
Am. J. Nephrol., 26(4):400-7 (2006)
Volume progression in polycystic kidney disease.
N. Engl. J. Med., May;354(20):2122-30 (2006)
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.
J. Am. Soc. Nephrol., Mar;17(3):854-62 (2006)
Chinese herb nephropathy.
Proc (Bayl Univ Med Cent)., Oct;13(4):334-7 (2000)
The failed renal transplant: in or out?
Semin Dial., 18(3):188-9 (2005 May-Jun)
Current status of kidney and pancreas transplantation in the United States, 1994-2003.
Am. J. Transplant., Apr;5(4 Pt 2):904-15 (2005)
Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity.
Transplantation., Feb;79(4):419-26 (2005)
V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment.
J. Am. Soc. Nephrol., Apr;16(4):838-9 (2005)
Cardiovascular complications of immunosuppressive agents in renal transplant recipients.
Expert Opin Drug Saf., Jan;4(1):29-44 (2005)
Disseminated intravascular coagulation (DIC) in a kidney donor associated with transient recipient DIC.
Am. J. Transplant., Feb;5(2):412-4 (2005)
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
Kidney Int., Sep;66(3):1193-8 (2004)
Morbid obesity does not preclude successful renal transplantation.
Clin Transplant., Feb;18(1):89-93 (2004)
Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
Kidney Int., Apr;65(4):1262-71 (2004)
Cyclosporin induces renal proto-oncogene RNA message and increased transforming growth factor-beta prior to renal fibrosis: Modification by calcium channel blockade in the salt replete rat.
Nephrology (Carlton)., Apr;9(2):58-64 (2004)
Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.
Transplantation., Mar;77(5):683-6 (2004)
Pharmacology of immunosuppressive drugs.
Drugs Today., May;34(5):463-79 (1998)
Off-label use of approved drugs: therapeutic opportunity and challenges.
J. Am. Soc. Nephrol., Mar;15(3):830-1 (2004)
A novel missense mutation in AE1 causing autosomal dominant distal renal tubular acidosis retains normal transport function but is mistargeted in polarized epithelial cells.
J. Biol. Chem., Apr;279(14):13833-8 (2004)
Ethical conflicts for physicians treating ESRD patients.
Semin Dial., 17(1):1-3 (2004 Jan-Feb)
Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients.
Am. J. Transplant., Jan;4(1):87-93 (2004)
Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
Kidney Int., Dec;64(6):2214-21 (2003)
Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.
Am. J. Transplant., Dec;3(12):1550-9 (2003)
Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension.
Am. J. Transplant., Sep;1(3):222-7 (2001)
Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.
Curr Opin Crit Care., Dec;7(6):384-9 (2001)
Relationship between nonphenacetin combined analgesics and nephropathy.
Kidney Int., Nov;60(5):2039 (2001)
Use of basiliximab and daclizumab in kidney transplantation.
Prog Transplant., Mar;11(1):33-7; quiz 38-9 (2001)
Renal toxicity of protease inhibitors.
Curr. Opin. Nephrol. Hypertens., Sep;9(5):473-6 (2000)
Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.
Kidney Int., Sep;58(3):1174-85 (2000)
The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy.
Transplantation., May;69(10):2149-53 (2000)
Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.
Am. J. Kidney Dis., Feb;35(2):333-46 (2000)
A practical guide to the management of hypertension in renal transplant recipients.
Drugs., Dec;58(6):1011-27 (1999)
Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis.
Kidney Int., Dec;56(6):2147-59 (1999)
Drug-related renal dysfunction in the elderly.
Geriatr Nephrol Urol., 9(1):21-5 (1999)
An animal model of chronic cyclosporine nephrotoxicity.
Ren Fail., 21(3-4):365-8 (1999 May-Jul)
The impact of generic drugs on the cost of transplantation medical care.
Transplant. Proc., May;31(3A Suppl):31S-34S (1999)
Pharmacoeconomics of immunosuppressive agents in renal transplant recipients.
Transplant. Proc., May;31(3A Suppl):6S (1999)
Effects of FK506 in rat and human resistance arteries.
Kidney Int., Apr;55(4):1518-27 (1999)
Renal complications after heart transplantation.
Transplant. Proc., 31(1-2):88 (1999 Feb-Mar)
Interaction between tacrolimus and nefazodone in a stable renal transplant recipient.
Pharmacotherapy., 18(6):1356-9 (1998 Nov-Dec)
The nephrotoxicity of new and old immunosuppressive drugs.
Ren Fail., Sep;20(5):687-90 (1998)
Efficacy and safety of low molecular weight heparin in renal transplantation.
Transplantation., Aug;66(4):533-4 (1998)
Cyclosporine arteriolopathy: effects of drug withdrawal.
Am. J. Kidney Dis., Aug;32(2):247-53 (1998)
Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner.
Kidney Int., Jul;54(1):216-23 (1998)
Chronic cyclosporine nephrotoxicity.
Curr. Opin. Nephrol. Hypertens., May;7(3):265-70 (1998)
Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insight.
J. Nephrol., 11(2):70-5 (1998 Mar-Apr)
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
Kidney Int., Apr;53(4):897-908 (1998)
Dr. William Bennett M